Details of the Drug

General Information of Drug (ID: DM9J6C2)

Drug Name
Tetracaine
Synonyms
Amethocaine; Anetain; Contralgin; Dicain; Dicaine; Dikain; Fissucain; Intercain; Laudocaine; Medicaine; Meethobalm; Metraspray; Mucaesthin; Niphanoid; Pontocaine; Rexocaine; Tetracaina; Tetracainum; Tetrakain; Uromucaesthin; Tetrakain [Czech]; Amethocaine (TN); Diaethylaminoaethanol ester der p-butylaminobenzoesaeure;Diaethylaminoaethanol ester der p-butylaminobenzoesaeure [German]; Medihaler-Tetracaine; Pontocaine (TN); Tetracaina [INN-Spanish]; Tetracaine [USAN:INN]; Tetracainum [INN-Latin]; Dimethylaminoethyl p-butyl-aminobenzoate; Tetracaine (USP/INN); P-Butylaminobenzoyl-2-dimethylaminoethanol; BENZOIC ACID,4-BUTYLAMINO,2-DIMETHYLAMINOETHYL ESTER PANTOCAIN BASE; P-(Butylamino)benzoic acid, 2-(dimethylamino)ethyl ester; BENZOIC ACID, p-(BUTYLAMINO)-, 2-(DIMETHYLAMINO)ETHYL ESTER; Benzoic acid, 4-(butylamino)-, 2-(dimethylamino)ethyl ester; 2-(Dimethylamino)ethyl 4-(butylamino)benzoate; 2-(Dimethylamino)ethyl p-(butylamino)benzoate; 2-Dimethylaminoethylester kyseliny p-butylaminobenzoove; 2-Dimethylaminoethylester kyseliny p-butylaminobenzoove [Czech]; 2-dimethylaminoethyl 4-(butylamino)benzoate; 4-(Butylamino)benzoic acid 2-(dimethylamino)ethyl ester; 4-[Butylamino]benzoic acid-2-[dimethylamino]ethyl ester
Indication
Disease Entry ICD 11 Status REF
Spinal anesthesia MB40.3 Approved [1]
Pain MG30-MG3Z Phase 2 [2]
Therapeutic Class
Anesthetics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 264.36
Topological Polar Surface Area (xlogp) 3.7
Rotatable Bond Count (rotbonds) 9
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
Metabolism
The drug is metabolized via plasma esterases [3]
Chemical Identifiers
Formula
C15H24N2O2
IUPAC Name
2-(dimethylamino)ethyl 4-(butylamino)benzoate
Canonical SMILES
CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C
InChI
InChI=1S/C15H24N2O2/c1-4-5-10-16-14-8-6-13(7-9-14)15(18)19-12-11-17(2)3/h6-9,16H,4-5,10-12H2,1-3H3
InChIKey
GKCBAIGFKIBETG-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
5411
ChEBI ID
CHEBI:9468
CAS Number
94-24-6
DrugBank ID
DB09085
TTD ID
D08HQK
VARIDT ID
DR00562
ACDINA ID
D01479

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Voltage-gated sodium channel alpha Nav1.8 (SCN10A) TT90XZ8 SCNAA_HUMAN Inhibitor [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Spinal anesthesia
ICD Disease Classification MB40.3
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Voltage-gated sodium channel alpha Nav1.8 (SCN10A) DTT SCN10A 9.89E-01 -0.16 -0.31
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
methylparaben E00149 7456 Antimicrobial preservative
Propylparaben sodium E00567 23679044 Antimicrobial preservative
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Eucalyptol E00063 2758 Flavoring agent
Lauric diethanolamide E00176 8430 Surfactant; Viscosity-controlling agent
Trolamine E00151 7618 Alkalizing agent; Emulsifying agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Water E00035 962 Solvent
Diazolidinyl urea E00354 62277 Antimicrobial preservative
⏷ Show the Full List of 10 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Tetracaine 1% cream 1% Cream Topical
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Evaluation of a novel topical anesthetic agent for cutaneous laser resurfacing: a randomized comparison study. Dermatol Surg. 2002 Nov;28(11):1004-6; discussion 1006.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4 Heterologous expression and functional analysis of rat Nav1.8 (SNS) voltage-gated sodium channels in the dorsal root ganglion neuroblastoma cell line ND7-23. Neuropharmacology. 2004 Mar;46(3):425-38.
5 Structures of muO-conotoxins from Conus marmoreus. I nhibitors of tetrodotoxin (TTX)-sensitive and TTX-resistant sodium channels in mammalian senso... J Biol Chem. 2004 Jun 11;279(24):25774-82.
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
7 Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
8 Pathobiology of visceral pain: molecular mechanisms and therapeutic implications. II. Genetic approaches to pain therapy. Am J Physiol Gastrointest Liver Physiol. 2000 Apr;278(4):G507-12.
9 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
10 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
11 Oral Administration of PF-01247324, a Subtype-Selective Nav1.8 Blocker, Reverses Cerebellar Deficits in a Mouse Model of Multiple Sclerosis. PLoS One. 2015; 10(3): e0119067.